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Background. Nongonococcal urethritis (NGU) is a common chlamydia-associated syndrome in men; however,
Trichomonas vaginalis and Mycoplasma genitalium are associated with its etiology and should be considered in
approaches to therapy. We sought to determine whether the addition of tinidazole, an anti-trichomonal agent, to the
treatment regimen would result in higher cure rates than those achieved with treatment with doxycycline or azithromycin
alone. A secondary aim was to compare the efficacy of doxycycline therapy and with that of azithromycin therapy.
Methods. Randomized, controlled, double-blinded phase IIB trial of men with NGU. Participants were
randomized to receive doxycycline plus or minus tinidazole or azithromycin plus or minus tinidazole and were
observed for up to 45 days.
Results.The prevalences of Chlamydia trachomatis,M. genitalium, and T. vaginalis were 43%, 31%, and 13%, respectively.
No pathogens were identified in 29% of participants. Clinical cure rates at the first follow-up visit were 74.5% (111 of 149
patients) for doxycycline-containing regimens and 68.6% (107 of 156 patients) for azithromycin-containing regimens. By
the final visit, cure rates were 49% (73 of 149 patients) for doxycycline-containing regimens and 43.6% (68 of 156
patients) for azithromycin-containing regimens. There were no significant differences in clinical response rates among the
treatment arms. However, the chlamydia clearance rate was 94.8% (55 of 58 patients) for the doxycycline arm and 77.4%
(41 of 53 patients) for the azithromycin arm (P 5 .011), and the M. genitalium clearance rate was 30.8% (12 of 39
patients) for the doxycycline arm and 66.7% (30 of 45 patients) for the azithromycin arm (P 5 .002).
Conclusions. Addition of tinidazole to the treatment regimen did not result in higher cure rates but effectively
eradicated trichomonas. Clinical cure rates were not significantly different between patients treated with doxycycline
and those treated with azithromycin; however, doxycycline had significantly better efficacy against Chlamydia,
whereas azithromycin was superior to doxycycline for the treatment of M. genitalium.
Urethritis in males that is not caused by gonorrhea is
classified as nongonococcal urethritis (NGU). NGU is
the most common urethritis syndrome seen in men in
the United States; in the past, p to 40% of NGU cases
were attributed to Chlamydia trachomatis, and as many
as 40% of cases were of unknown etiology [1–3].
However, there has not been a comprehensive re-
evaluation of the therapy for NGU in 15 years [4]. Since
that time, there have been data suggesting that addi-
tional pathogens may play an important role in the
etiology of NGU and should be considered in ap-
proaches to therapy. Newer studies using more-sensitive
diagnostic techniques have implicated other pathogens
in the etiology of NGU including Mycoplasma
genitalium and Trichomonas vaginalis [5, 6]. We hy-
pothesized that currently recommended initial therapies
for NGU, doxycycline and azithromycin, might be im-
proved by the addition of antimicrobial coverage for T.
vaginalis. We further hypothesized that, of the 2 cur-
rently recommended initial treatment regimens for
NGU, azithromycin therapy would result in a higher
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clinical cure rate than doxycycline therapy because azi-
thromycin, compared with doxycycline, apparently has greater
efficacy against M. genitalium [7] and is reported to have
equivalent efficacy against C. trachomatis [4].
METHODS
We conducted a randomized, controlled, double-blinded
phase IIB treatment study of NGU. The primary aim was to
determine whether the addition of tinidazole, a proven anti-
trichomonal agent [8], to the recommended treatment regi-
men for NGU [9] would be tolerable and more efficacious
than treatment with either doxycycline or azithromycin alone.
Tinidazole was chosen over metronidazole because of
the former’s superior penetration into the male genital tract
tissues [10]. A secondary aim was to compare doxycycline
treatment with azithromycin treatment for NGU with
respect to the effect of each treatment drug on M. genitalium.
This aim was motivated by accumulating data suggesting
that doxycycline may lack clinical efficacy against
M. genitalium, which plays a prominent role in the patho-
genesis of NGU.
The study evaluated the efficacy of doxycycline administered
in a 100-mg oral dose twice daily for 7 days plus or minus
tinidazole administered in a single 2-g oral dose and the efficacy
of azithromycin administered in a single 1-g oral dose plus or
minus tinidazole administered in a single 2-g oral dose.
Study participants were heterosexual men 16–45 years of age
who attended sexually transmitted disease (STD) clinics in
Birmingham, Alabama; New Orleans, Louisiana; Durham,
North Carolina; and Baltimore, Maryland. NGU was defined as
new-onset urethral discharge or dysuria and a urethral smear
with >5 polymorphonuclear leukocytes (PMNs) per 3–5 oil
immersion fields without evidence of gonorrhea [9]. Partic-
ipants were excluded from the study for the following reasons:
a test result positive for gonorrhea at the baseline visit; history of
recurrent NGU (>3 episodes within the previous year) or his-
tory of recent NGU (within the previous 30 days); signs or
symptoms of epididymitis or prostatitis; known allergy to study
drugs; receipt of systemic antibiotics within 30 days of enroll-
ment; presence of concomitant infection that required anti-
biotics; unwillingness to abstain from alcohol for 24 h after
enrollment; serious underlying infection, including known HIV
infection or other primary or secondary immunosuppression; or
voided within the hour preceding evaluation.
After consent was obtained, participants were asked questions
regarding their sexual history and current symptoms. The
presence of urethral discharge was confirmed. A urethral swab
specimen was obtained for T. vaginalis nucleic acid amplifica-
tion testing (NAAT), and a first fraction urine specimen was
obtained for gonorrhea, chlamydia, M. genitalium, and T.
vaginalis NAAT. Participants were asked to abstain from sexual
intercourse or use condoms during the study period. Partic-
ipants who tested positive for Neisseria gonorrhoeae were noti-
fied to return immediately for treatment according to local
guidelines and were discontinued from the study.
Participants were randomized using a block randomization
scheme with blocks of size 16 stratified by clinical center to 1 of 4
treatment arms: (1) doxycycline, (2) doxycycline plus tinidazole,
(3) azithromycin, or (4) azithromycin plus tinidazole. The single
doses of tinidazole and azithromycin (active or placebo) were
directly observed. Participants were counseled regarding partner
notification and treatment as well as abstinence and condom use.
Participants were asked to return in 1 week after completion
of therapy (days 15–19). They were queried regarding interim
sexual activity, symptoms, and possible adverse effects of the
study medication. A genital examination was performed to de-
termine the presence or absence of urethral discharge. Two
urethral swab specimens were obtained for staining and quan-
tifying PMNs on the urethral smear and for T. vaginalis PCR.
A urine specimen was obtained for detection of N. gonorrhoeae,
C. trachomatis, T. vaginalis, and M. genitalium. Participants with
persistent symptoms and objective signs of NGU were dis-
continued from the study and treated according to local
guidelines for recurrent or persistent urethritis. The final
study visit was conducted during days 35–45 using the same
procedures.
Definition of clinical cure varied slightly according to the
study visit and was modeled after definitions used by Stamm
et al [4] in the last major study of NGU treatment, which served
as the historical benchmark for this study. At the first follow-up
visit, clinical failure was defined as persistent symptoms and .5
PMNs per 3–5 oil immersion fields on the urethral smear (re-
gardless of urethral discharge) or persistent urethral discharge
on examination (regardless of symptoms or number of PMNs).
At the final study visit, clinical failure was defined as .5 PMNs
per 3–5 oil immersion fields alone (regardless of symptoms or
presence of urethral discharge) or persistent urethral discharge
on examination (regardless of symptoms or number of PMNs).
Participants who failed to return and/or were not evaluated for
any reason were designated as unevaluable. Participants who
met the criteria for clinical failure at any visit were discontinued
from the study and added to the cumulative failures for the
study. Efficacy was based on the last visit for which the person
had a clinical response determined.
Microbiological Methods
Urethral Gram stains were performed at the clinic sites to quan-
titate PMNs and determine the presence or absence of gram-
negative diplococci. At each clinical site, urine specimens were
mixed and aliquoted into transport media for the assay for
N. gonorrhoeae and C. trachomatis. This testing was performed in
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accordance with the manufacturer’s instructions using the li-
censed GEN-PROBE TMA assay (Aptima Combo II; Gen-Probe).
Detection of M. genitalium in urine was performed centrally
at Louisiana State University using the GEN-PROBE TMA-HPA
M. genitalium analyte-specific reagent assay (Gen-Probe). PCR
testing for T. vaginalis was performed centrally at the University
of Alabama at Birmingham, as previously described [11].
Sample Size Estimation
It was hypothesized that conventional therapy (with azi-
thromycin or doxycycline) would be at least 70% effective. For
each conventional therapy agent, the sample size was estimated
using the Mantel-Haenszel-Cochran test without continuity
correction to adjust for stratification across 4 clinical centers.
With 75 patients in each arm, an improvement in clinical cure
rate to 89% within each parallel trial could be detected between
a conventional therapy arm minus tinidazole and the corre-
sponding arm plus tinidazole at the 1-sided .05 significance level
with power of .90. Sample size was determined on the basis of
response at the last evaluable visit.
Statistical Methods
The primary analysis population for efficacy and safety was the
modified intent-to-treat (MITT) population, which comprised
all participants randomized who received at least 1 dose of study
drug therapy or placebo. Confirmatory analyses were performed
with the per protocol population (n 5 200), which did not
include participants who did not meet eligibility criteria (n
5 12), had protocol deviations potentially affecting the primary
endpoint (n 5 8), or did not adhere to the protocol visit
schedule (n 5 85).
For each of the treatment groups, the binomial proportion
and its 95% confidence interval were used to estimate clinical
cure rate. The stratified Mantel-Haenszel-Cochran test was used
to evaluate the addition of tinidazole to each conventional
therapy and to compare the 2 conventional therapies across the
4 clinical sites (strata). For each treatment group, the prevalence
and microbiological cure rate for each organism (C. trachomatis,
T. vaginalis, and M. genitalium) were estimated using the bi-
nomial proportions and 95% confidence intervals. For micro-
biological cure rates, the overall group effect was assessed using
v2 tests, and when significant, pairwise comparisons were made.
RESULTS
A total of 305 study participants were randomized and included
in the MITT population, as follows: 76 received doxycycline, 73
received doxycycline plus tinidazole, 77 received azithromycin,
and 79 received azithromycin plus tinidazole (Figure 1). The
first subject was enrolled in November 2006, and the last follow-
up visit was completed in April 2009.
The randomization groups were similar with respect to
their baseline demographic characteristics and sexual history
(Table 1). The median number of lifetime sexual partners was
20, whereas the median number of partners within the previous
30 days was 1. On average, 7 days had elapsed between the last
time that participants had engaged in sexual activities and the
time they presented for care. In terms of symptoms, 55% pre-
sented with urethral discharge only, 5% presented with dysuria
only, and 40% presented with both discharge and dysuria.
Screening, Enrollment, and Follow-up
Of the 313 individuals screened for the protocol, 305 (97%) were
enrolled. Of the 8 individuals who were eliminated at screening,
2 had gonorrhea and 6 did not have >5 PMNs on urethral
smear (1 of whom also did not have the required symptoms).
Eighty-two percent of study participants completed the first
follow-up visit, and 56% completed the second follow-up visit.
Of those who discontinued the study early, 41% discontinued
because of clinical failure at the first follow-up visit; having
reached a specified study end point, their study discontinuation
was in accordance with the protocol. Most of the other
participants who terminated study participation before com-
pleting the second follow-up visit were lost to follow-up. The
percentage of patients who were lost to follow-up varied by
clinic and ranged from 15% at the Birmingham site to 42% at
the New Orleans site, but this rate did not differ significantly
according to treatment arm, with rates of loss to follow-up
ranging from 18% for the doxycycline arm to 31% for the
azithromycin arm.
Figure 1. Study flow diagram. aThe results of a gonorrhea test
performed at screening were reported to be positive after randomization.
bAll randomized participants were analyzed in a modified intent-to-treat
analysis.
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Prevalence of Pathogens at Baseline
The distribution of pathogens detected at baseline is shown in
Figure 2. The prevalence of chlamydia was 43%, whereas the
prevalence of M. genitalium was 31%. T. vaginalis was detected
in 13% of participants (in urine or swab samples). None of the 3
pathogens were identified in 29% of participants. Sixteen per-
cent of men had multiple pathogens detected, with the most
common combination being C. trachomatis and M. genitalium
(8%). No significant differences among treatment arms were
detected with respect to the proportion of patients who tested
positive for chlamydia (P 5 .35), M. genitalium (P 5 .96),
trichomonas (P 5 .66) or with respect to the distribution of
gram stain PMNs (P 5 .77).
Efficacy Response by Study Visit
In the MITT population, in which participants who were lost to
follow-up (ie, unevaluable) were counted as having experienced
treatment failure, clinical cure rates at the first follow-up visit were
74.5% for doxycycline-containing regimens combined and 68.6%
for azithromycin-containing regimens combined (Table 2). The

















(n 5 305) Pa
Age, mean years (6SD) 27.3 6 7.0 27.8 6 6.8 26.4 6 6.7 25.7 6 7.2 26.8 6 6.9 .243
Race 74 (97) 72 (99) 76 (99) 77 (97) 299 (98)
Black or African American .953
White/other 2 (3) 1 (1) 1 (1) 2 (3) 6 (2)
Education level 19 (25) 13 (18) 16 (21) 21 (27) 69 (23)
No high school degree .543
Vocational, technical, or trade school certificate 1 (1) 0 (0) 0 (0) 0 (0) 1 (,1)
High school graduate or GED 33 (43) 35 (48) 39 (51) 34 (43) 141 (46)
Some college 17 (22) 22 (30) 21 (27) 22 (28) 82 (27)
Bachelor’s degree or higher 6 (8) 3 (4) 1 (1) 2 (3) 12 (4)
New sexual partners in previous 30 days,
median no. of partners (range)
0 (0–3) 0 (0–3) 0 (0–4) 0 (0–27) 0 (0–27) .738
Episodes of vaginal sex in the previous 30 days,
median no. of episodes (range)
5 (0–40) 5 (0–50) 4 (0–90) 5 (0–30) 5 (0–90) .962
Episodes of receptive oral sex in the previous 30 days,
median no. of episodes (range)
2 (0–30) 1 (0–30) 2 (0–90) 2 (0–30) 2 (0–90) .674
Different sexual partners in the previous 3 months,
median no. of partners (range)
2 (1–6) 2 (0–20) 2 (0–30) 2 (1–100) 2 (0–100) .297
Condom use during most recent sexual encounter 48 (63) 51 (70) 48 (62) 39 (49) 186 (61)
No .066
Yes 27 (36) 22 (30) 29 (38) 40 (51) 118 (39)
Missing data 1 (1) 0 (0) 0 (0) 0 (0) 1 (,1)
Did the condom break or come off? 20 (26) 19 (26) 15 (19) 22 (28) 76 (25)
No .025 b
Yes 7 (9) 3 (4) 14 (18) 18 (23) 42 (14)
Not applicable 49 (64) 51 (70) 48 (62) 39 (49) 187 (61)
How often was a condom used in the
previous 3 months?
Never 16 (21) 19 (26) 12 (16) 9 (11) 56 (18) .137
Almost never 6 (8) 5 (7) 5 (6) 5 (6) 21 (7)
Sometimes 24 (32) 17 (23) 23 (30) 16 (20) 80 (26)
Almost always 26 (34) 27 (37) 29 (38) 30 (38) 112 (37)
Always 3 (4) 4 (5) 8 (10) 14 (18) 29 (10)
Do not know/missing data 1 (1) 1 (1) 0 (0) 5 (6) 7 (2)
NOTE. Data are no. (%) of subjects, unless otherwise indicated. GED, general educational development certificate; SD, standard deviation.
a Exact v2 or nonparametric Kruskal-Wallis test for differences among treatment arms. When statistically significant, additional 2-sided pairwise tests were
performed. Missing data, not applicable, and do not know categories were excluded from P value calculations.
b P 5 .488 for doxycycline therapy arm versus doxycycline 1 tinidazole therapy arm; P 5 .810 for azithromycin therapy arm versus azithromycin plus tinidazole
therapy arm.
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addition of tinidazole to either regimen did not benefit clinical
cure rates. As of the final study visit, cumulative cure rates
were 49% for doxycycline-containing regimens and 43.6% for
azithromycin-containing regimens. The primary hypotheses
comparing doxycycline versus doxycycline plus tinidazole
(P 5 .34, 1-sided) and azithromycin versus azithromycin plus
tinidazole (P 5 .12, 1-sided) were both nonsignificant. There
were no significant differences among any of the 4 treatment
arms. Results for the per protocol population were consistent
with those for the MITT population.
Of the 82 individuals defined as having experienced clinical
failure at the final study visit, 53 (65%) of 82 were defined as such
solely on the basis of a urethral smear showing .5 PMNs. If these
participants were classified as having experienced cure, there
would still be no difference in the efficacy of the treatment arms.
Microbiological Efficacy
The 4 treatment arms differed significantly in the proportions of
participants with chlamydial infection at baseline who had
negative results after treatment (P 5 .017) (Table 3). The
chlamydia clearance rate was 94.8% (55 of 58 participants) for
those who received doxycycline with or without tinidazole and
was 77.4% (41 of 53) for those who received azithromycin with
or without tinidazole (P 5 .011, 2-sided).
The 4 treatment arms also differed significantly with respect
to the proportion of participants with M. genitalium infection
after treatment of participants who had positive results at
baseline (P 5 .008). The M. genitalium clearance rate was 30.8%
(12 of 39 participants) for those who received doxycycline with
or without tinidazole and 66.7% (30 of 45) for those who re-
ceived azithromycin with or without tinidazole (P 5 .002, 2-
sided).
Only 1 (5%) of 20 tinidazole-treated participants with tri-
chomonas (detected in urine or swab samples) at baseline had
results that remained positive for this infection at follow-up.
Among those participants not receiving specific treatment for
trichomonas, 5 (31%) of 16 had PCR results that were positive
for this pathogen at their follow-up visits. Thus, 11 (69%) of 16
men who had T. vaginalis detected at baseline and did not re-
ceive tinidazole had apparent spontaneous resolution of the
infection (confirmed in urine and swab samples). Of these
participants, 8 (73%) of 11 had cleared the infection at the first
















Follow-up visit 1 10 (13) 7 (10) 8 (10) 8 (10) 33 (11)
Clinical failure
Clinical cure 57 (75) 54 (74) 52 (68) 55 (70) 218 (71)
Unevaluable 9 (12) 12 (16) 17 (22) 16 (20) 54 (18)
Follow-up visit 2 22 (29) 17 (23) 24 (31) 19 (24) 82 (27)
Clinical failure
Clinical cure 22 (29) 24 (33) 19 (25) 25 (32) 90 (30)
Unevaluable 22 (29) 25 (34) 26 (34) 27 (34) 100 (33)
Treatment failure at visit 1 10 (13) 7 (10) 8 (10) 8 (10) 33 (11)
Cumulative efficacy outcomea 32 (42) 24 (33) 32 (42) 27 (34) 115 (38)
Clinical failure
Clinical cure 36 (47) 37 (51) 30 (39) 38 (48) 141 (46)
Unevaluable 8 (11) 12 (16) 15 (19) 14 (18) 49 (16)
Exact 95% CI for cure rate 40.8–64.2 37.4–61.3 20.8–50.7 40.4–63.3
NOTE. Data are no. (%) of subjects, unless otherwise indicated. CI, confidence interval. P . .05 for cure rate.
a Subjects who met the criteria for clinical failure at any visit were discontinued from the study and added to the cumulative failures and those who did not return
for any follow-up (unevaluable) were counted as treatment failures. Therefore the number cured for the cumulative efficacy outcome was the total number of
subjects minus treatment failures minus those who did not return for any follow-up (unevaluable).
Figure 2. Prevalence of pathogens at baseline.
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follow-up visit, and 3 (27%) of 11 had cleared the infection by
the second follow-up visit. Interim use of metronidazole could
only be documented for 1 of these individuals. Among those
participants in whom T. vaginalis infection resolved and in
whom it was the only pathogen detected, 8 (72.7%) of 11 met
the definition of clinical cure of NGU. None of the 4 participants
who failed to clear T. vaginalis in the doxycycline or azi-
thromycin only arms were deemed to have experienced clinical
cure.
Participant Adherence to the Protocol
Only 2% of participants reported taking antibiotics other than
the study drugs during follow-up. At the first follow-up visit,
61% of participants were adherent to therapy, which was
defined as taking at least 80% of the medications, as determined
on the basis of pill count. No significant differences among
study groups were detected with respect to medication
adherence.
At the first follow-up visit, the median number of sexual
partners and median number of new sexual partners reported
since the baseline visit were 1.0 and 0, respectively. There were
no significant differences among the 4 treatment arms with re-
spect to sexual behavior with the exception of frequency of re-
ceptive oral sex (P 5 .009). The pairwise comparison between
therapy with azithromycin only and therapy with azithromycin
plus tinidazole was statistically significant (P 5 .01). At the
second follow-up visit, the median number of sexual partners
and median number of new sexual partners reported since the
last visit were 1.0 and 0, respectively. There were no significant
differences among the 4 treatment arms with respect to sexual
behavior. At the first follow-up visit, 75% of participants who
reported having sex since the last visit reported always using
a condom. Seventy-seven percent stated that they had used
a condom during their most recent sexual encounter. At the
second follow-up visit, 57% of participants who had had sex
since the previous visit reported always using a condom. Se-
venty-one percent stated that they had used a condom during
their most recent encounter. There were no significant differ-
ences among the 4 treatment arms with respect to frequency of
condom use or condom use for the most recent sexual en-
counter at either follow-up visit.
Adverse Events
Study drugs were well tolerated, with similar rates of adverse
events reported for the 4 study arms. The most frequently re-
ported adverse events were nausea, vomiting, abdominal pain,
diarrhea, and taste abnormality (Table 4). Only 1 severe (grade
3) event, diarrhea, was reported.
Table 3. Microbiologic Cure Rate
Last available result for subjects











Chlamydia 0 3 7 5 15
Positive .02c
Negative 34 21 19 22 96
Missing data 4 4 3 9 20
Prevalence (exact 95% CI)b 0 (0–10.3) 12.5 (2.7–32.4) 26.9 (11.6–47.8) 18.5 (6.3–38.0)
Trichomonas in swab/urine samplesd 3 0 2 1 6
Positive .35e
Negative 6 9 5 4 24
Missing 2 3 2 3 10
Prevalence (exact 95% CI)b 33.3 (7.5–70.1) 0 (0–33.6) 28.6 (3.7–71.0) 20.0 (0.5–71.6)
Mycoplasma genitalium 16 11 9 6 42
Positive .005f
Negative 5 7 13 17 42
Missing data 1 4 3 2 10
Prevalence (exact 95% CI)b 76.2 (52.8–91.8) 61.1 (35.8–82.7) 40.9 (20.7–63.7) 26.1 (10.2–48.4)
NOTE. AZI, azithromycin; CI, confidence interval; DOX, doxycycline; T, tinidazole.
a v2 of overall group effect (DOX vs DOX 1 T vs AZI vs AZI 1 T).
b Missing values excluded from the denominator of prevalence (%) calculations.
c P values for subsequent a priori specified pairwise comparisons: DOX vs DOX1 T, P 5 .97 (1-sided); AZI vs AZI1 T, P 5 .26 (1-sided); (DOX, DOX1 T) vs (AZI,
AZI 1 T), P 5 .01 (2-sided); [DOX, AZI] vs. [DOX 1 T, AZI 1 T], P 5 .59 (2-sided).
d All subjects were tested for trichomonas at baseline using tests performed on both swab and urine samples with results that were 93% concordant. Subjects
were considered to be positive for infection at baseline if they had positive results on either test. Those subjects who were positive at baseline underwent follow-up
testing of both urine and swab samples, which had results that were 100% concordant at the final follow-up visit.
e No subsequent pairwise comparisons performed, because the overall group effect was nonsignificant as specified a priori.
f P values for subsequent a priori specified pairwise comparisons: DOX vs DOX1 T, P 5 .24 (1-sided); AZI vs AZI1 T, P 5 .18 (1-sided); (DOX, DOX1 T) vs (AZI,
AZI 1 T), P 5 .002 (2-sided); [DOX, AZI] vs [DOX 1 T, AZI 1 T], P 5 .19 (2-sided).
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DISCUSSION
Nongonoccoccal urethritis is a common clinical syndrome.
Recommended initial treatment regimens primarily target C.
trachomatis as the etiology, although the contributions of other
pathogens, including T. vaginalis and M. genitalium, have been
increasingly reported [5, 6, 12–19]. In one study, trichomonas
was nearly as common as chlamydia (17.3% vs 19.6%) [6].
Despite this, current recommendations are to include anti-
trichomonal therapy only for men with persistent NGU [9]. In
terms of M. genitalium, Mena et al [13] found a prevalence of
21% among men with symptomatic NGU. The optimal therapy
for M. genitalium remains unclear, because treatment failure has
been reported for both doxycycline and azithromycin therapy
[20]. Interestingly, older studies found that NGU caused by
chlamydia responded significantly better to tetracyclines than
did cases of NGU in which no chlamydia was found [21, 22].
In our study, tinidazole did not enhance the clinical cure rates
of conventional therapy for NGU. This finding may be attrib-
utable to the lower-than-anticipated prevalence of trichomonas
among study participants and the high rate of spontaneous re-
gression of trichomonas in the absence of tinidazole. Sponta-
neous resolution of trichomonas from the urethra has been
previously reported [23, 24]. Of note, among those men with
trichomonas who received tinidazole, only 1 microbiological
failure occurred.
Important findings in our study were the significant differences
in the microbiologic cure rates for M. genitalium and, especially,
C. trachomatis following treatment with doxycycline or azi-
thromycin. Azithromycin was significantly more effective against
M. genitalium than was doxycyline; however, doxycycline therapy
offered superior efficacy over azithromycin therapy for chla-
mydia. Failure to cure M. genitalium with both doxycline and
azithromycin therapy has been previously documented [7, 25,
26], and one randomized study showed azithromycin therapy to
be more efficacious than doxycycline therapy [20]. However, we
are unaware of clinical studies that have shown doxycycline to be
superior to azithromycin for the treatment of C. trachomatis.
Clearly, these are important topics for additional study.
In our study, cure rates were lower than those reported by
Stamm et al [4]. Reasons for lower clinical cure rates could
include the high rate of C. trachomatis infection coupled with
the lower observed efficacy of azithromycin therapy for this
infection in our study, as well as potential re-infections in this
high-risk population. Finally, it is possible that there has been
a real decrease in response to therapy for NGU over the previous
2 decades. Compared with rates of cure in clinical practice, rates
of cure at the final study visit are underestimated, because the
majority of clinical cures in our study and in that of Stamm et al
[4] were based solely on the persistence of neutrophils and
would not have been recognized in the course of usual care,
a setting in which test-of-cure gram stains are not routinely
performed.
The limitations of our study include the aforementioned
lower-than-anticipated prevalence of trichomonas, coupled with
spontaneous regression of trichomonas in the absence of tini-
dazole. A larger sample size, which would have accounted for
these factors, may have been desirable. Our study population
was largely African American and may not be applicable to
a more diverse group of men.
In summary, the addition of tinidazole to doxycycline or
azithromycin therapy did not result in higher rates of clinical
cure but did effectively eradicate trichomonas. Clinical cure rates
were not significantly different between the doxycycline and
azithromycin arms. However, doxycycline therapy had signifi-
cantly better efficacy against Chlamydia, whereas azithromycin
therapy was superior for the treatment of M. genitalium in-
fection. Based on these data, it may be that management of
NGU, and especially of recurrent or persistent NGU, should be
guided by an etiologic diagnosis rather than by a syndromic
approach.
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